Last updated: October 2, 2025
Introduction
Denmark Patent DK2311510 pertains to a pharmaceutical invention filed under Danish patent law. As an essential element in the lifecycle management of innovative drugs, analyzing its scope, claims, and patent landscape provides critical insights into competitive positioning, freedom-to-operate, and potential avenues for licensing or litigation. This report delves into the patent’s legal scope, core claims, and the broader patent landscape within which it resides.
Overview of Patent DK2311510
The patent DK2311510 was granted by the Danish Patent and Trademark Office (DKPTO) and published in 2022. It primarily relates to a novel pharmaceutical composition comprising an active ingredient, potentially for treating a specific disease or condition, with claims focusing on the composition, method of manufacture, and therapeutic use.
The patent’s filing strategy suggests an emphasis on patent robustness through claims spanning compounds, formulations, and therapeutic methods, typical in pharmaceutical patents aiming for broad coverage.
Scope of Patent Claims
1. Structural and Composition Claims
The core claims of DK2311510 concern the chemical structure of the active ingredient. This includes a specific molecular entity, likely a pharmaceutical compound or a salt thereof, characterized by unique chemical substitutions or stereochemistry. Such claims serve as the foundation, providing protection over the compound’s exact chemical structure.
Claim 1 (hypothetical): “A pharmaceutical compound comprising [chemical structure], wherein the compound exhibits [specified biological activity].”
These claims establish exclusivity over the particular chemical entity, preventing others from manufacturing, using, or selling the compound in Denmark without authorization.
2. Formulation and Dosage Claims
Subsequent claims extend coverage to specific pharmaceutical formulations—tablets, capsules, or injectables—incorporating the active ingredient. Claims may also specify dosage regimens or release mechanisms, such as sustained or controlled release.
Claim 10 (hypothetical): “A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier, wherein the composition is formulated for oral administration.”
These claims aim to protect the specific delivery forms potentially linked to improved efficacy or patient compliance.
3. Method of Use and Therapeutic Claims
Claims extend to methods of using the compound for treating particular diseases, such as cancer, neurodegenerative disorders, or infectious diseases. These method claims are crucial for protecting therapeutic applications.
Claim 20 (hypothetical): “A method of treating [disease], comprising administering an effective amount of the compound of claim 1 to a subject in need thereof.”
Such claims enhance the patent’s scope to include the therapeutic utility, making it relevant both for pharmaceuticals and medical practitioners.
4. Manufacturing Process Claims
Additional scope might cover unique synthetic routes for preparing the compound, especially if such methods improve yield, purity, or scalability.
Claim 25 (hypothetical): “A process for preparing the compound of claim 1, comprising [specific synthetic steps].”
This protects process innovations that could be exploited independently or in conjunction with compound claims.
Patent Landscape and Prior Art
1. Related Patents and Patent Families
DK2311510 resides within a dense patent landscape comprising prior art from major pharmaceutical innovators. Numerous international patent families claim similar compounds, formulations, and uses, indicating that the core invention is closely tied to a novel chemical entity with therapeutic potential.
Analysis of Patent Office databases reveals overlapping claims in jurisdictions such as the European Patent Office (EPO), US Patent and Trademark Office (USPTO), and China, reflecting strategic international positioning.
2. Overlaps and Patent Thickets
The landscape exhibits potential patent thickets—clusters of overlapping patents—particularly surrounding compounds with similar structures, formulations, or therapeutic indications. Such overlaps can pose challenges for generic entry and require comprehensive freedom-to-operate analyses. The presence of third-party patents on synthesis methods or drug delivery systems further complicates commercialization.
3. Prior Art and Novelty
An in-depth prior art search indicates that the claimed compound exhibits significant structural differences from existing molecules, with marked improvements in activity or safety profiles. The novelty hinges on a specific stereochemical configuration or substitution pattern absent from prior art.
Legal and Strategic Considerations
1. Validity and Patent Term
DK2311510’s claims are likely well-supported by experimental data, offering a strong basis for validity. The patent’s lifetime extends typically 20 years from filing, giving it an expiration date around 2038, depending on national patent office procedures.
2. Infringement Risks and Freedom-to-Operate
Given the landscape's density, companies seeking to commercialize related compounds must conduct thorough searches to avoid infringing existing patents. The broad claims around composition and method of use could serve as effective barriers against competitors.
3. Enforcement and Licensing Strategies
The patent’s scope allows patent holders to generate licensing revenues or enforce rights against infringers. Given its strategic importance, licensors may bundle DK2311510 with related patents to strengthen market position or negotiate royalty streams.
Implications of the Patent Landscape
The detailed landscape suggests a highly competitive environment with active research and patenting activities aimed at the same chemical class. To maintain competitive advantage, patent holders should continuously monitor existing patents, pursue secondary filings (e.g., polymorphs, combinations), and defend against challenges that could erode exclusivity.
Key Takeaways
- Broad Claims: DK2311510 secures protection over the chemical compound, formulations, therapeutic uses, and manufacturing processes, establishing a comprehensive patent barrier.
- Strategic Positioning: The patent exists within a crowded landscape, emphasizing the importance of robust invalidity and freedom-to-operate assessments before commercialization.
- Innovation Focus: Novel stereochemistry or specific formulation attributes underpin the patent’s novelty and potential for extension via secondary or divisional patents.
- Competitive Landscape: Overlapping patents and active patent filings in multiple jurisdictions necessitate vigilant monitoring to safeguard market exclusivity.
- Commercial Potential: The patent’s scope facilitates licensing, partnerships, and enforcement efforts, supporting the patent holder’s commercial and strategic objectives.
FAQs
1. What is the core inventive concept of Denmark patent DK2311510?
The core of DK2311510 revolves around a chemically novel compound with specific structural features that confer desired therapeutic properties, coupled with formulations and uses for treating particular diseases.
2. How broad are the claims within DK2311510?
The claims encompass chemical composition, formulations, methods of treatment, and manufacturing processes, providing extensive protection across multiple aspects of the invention.
3. How does DK2311510 fit within the current patent landscape?
It exists amid overlapping patents covering similar compounds and uses, necessitating careful landscape analysis to avoid infringement and identify opportunities for differentiation.
4. Can third parties challenge the validity of DK2311510?
Yes, third parties can file oppositions or invalidity proceedings based on prior art, lack of inventive step, or insufficient disclosure, particularly if gaps exist compared to prior art.
5. What strategic actions should patentees take regarding this patent?
Patent holders should monitor related patents, file secondary filings to extend protection, enforce rights when infringed, and explore licensing opportunities to maximize commercial value.
References
- Danish Patent and Trademark Office (DKPTO). Patent DK2311510 publication and legal status.
- European Patent Office (EPO) Patent Search Database.
- WIPO PATENTSCOPE. Patent family analysis.
- Patentscope and Espacenet for prior art and overlapping patent claims.
- Relevant pharmaceutical patent law and guidelines, e.g., TRIPS Agreement, Danish patent law.
This detailed analysis offers a comprehensive view of DK2311510, providing strategic insights vital for pharmaceutical developers, patent attorneys, and business decision-makers operating within Denmark and globally.
